Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab
Authors:
Open Access
- 13 February 2026
- journal article
- research article
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Abstract
Immunotherapy has significantly improved the treatment of metastatic solid tumors; however, detecting early signs of response to enable timely intervention for resistant tumors remains challenging. A blood-only circulating tumor DNA (ctDNA) test may provide a rapid assessment of tumor response without reliance on matched tumor tissue. We applied a tissue-agnostic, genome-wide methylation enrichment assay, based on cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq), to plasma samples from patients in a phase 2 trial evaluating pembrolizumab across multiple solid tumors (NCT02644369). A decrease in ctDNA from baseline to pre-cycle 3 was significantly associated with higher objective response and clinical benefit rates and longer progression-free and overall survival in univariate analyses, with these associations remaining significant in multivariable models except for overall survival. These results validate a commercial-grade, tissue-agnostic plasma cfDNA methylation platform for immunotherapy response monitoring, which may facilitate earlier, more informed treatment decisions and improve patient outcomes.Keywords
This publication has 43 references indexed in Scilit:
- Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort studyBritish Journal of Cancer, 2024
- Clinical validation of a tissue-agnostic genome-wide methylome enrichment molecular residual disease assay for head and neck malignanciesAnnals of Oncology, 2024
- Immune checkpoint therapy—current perspectives and future directionsCell, 2023
- Evaluation of cell-free DNA approaches for multi-cancer early detectionCancer Cell, 2022
- Cell-free DNA methylation-defined prognostic subgroups in small-cell lung cancer identified by leukocyte methylation subtractioniScience, 2022
- Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNAAnnals of Oncology, 2020
- Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and diseaseNature Communications, 2018
- Erratum: Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolutionNature, 2017
- Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of OriginCell, 2014
- A solution to the problem of separation in logistic regressionStatistics in Medicine, 2002